Background-Several clinical risk estimation tools have established their role in the prediction of recurrence of acute coronary syndrome (ACS), but the value of genetic risk scores (GRSs) remains unclear. We examined how well 2 different GRSs estimate recurrent ACS and whether clinical factors are associated with GRSs. Methods and Results-A cohort of 2090 consecutive patients with ACS who underwent coronary angiography between July 2006 and March 2008 in a single tertiary center was genotyped and prospectively followed up for a median of 5.5 years. We formed 2 partially overlapping GRSs: GRS47 of 47 single-nucleotide polymorphisms with previously reported significant association with coronary artery disease and GRS153 of 153 single-nucleotide polymorphisms with significant or suggestive association with coronary artery disease. GRS47 showed association with recurrent ACS independent of clinical factors (P=0.037; hazard ratio, 1.17; 95% confidence interval, 1.01-1.36). GRS153 had no association with either recurrent ACS or composite of recurrent ACS or death. Also, GRS47 was associated inversely with smoking and STsegment-elevation myocardial infarction (P=0.004; odds ratio, 0.22; 95% confidence interval, 0.08-0.62 and P=0.041; odds ratio, 0.36; 95% confidence interval, 0.13-0.96, respectively). Conclusions-GRSs combined of 47 known coronary artery disease risk single-nucleotide polymorphisms were associated with recurrent ACS after multivariable adjustments in a heterogenic ACS population for the first time. Smoking and ST-segment-elevation myocardial infarction had an inverse association with the GRSs. The significance of smoking in relation to genetic coronary artery disease predisposition may merit further evaluation in patients with ACS.
C oronary artery disease (CAD) and acute coronary syndrome (ACS) are leading causes of death in developed countries. 1 In addition to traditional risk factors, also genetics play a key role in the atherosclerosis development. Genome-wide association analysis studies (GWASs) have identified a large number of loci that are related to the development of CAD or myocardial infarction (MI).
2-13 The CARDIoGRAMplusC4D Consortium specified 15 new loci to reach genome-wide significance in the largest GWAS to date. 3 Furthermore, they reported >100 single-nucleotide polymorphisms (SNPs) to be strongly associated with CAD but not to achieve the genome-wide significance level. Altogether, these variants explain 10.6% of CAD heritability. 3 
Clinical Perspective on p 178
Research concerning genetic risk scores (GRSs) combining multiple CAD risk variants is emerging. However, there is limited evidence that GRSs can be used to predict recurrence of ACS. The objective of this prospective cohort study was to evaluate the value of 2 different GRSs besides clinical risk factors in predicting recurrent ACS and CAD mortality among patients with ACS.
Methods
The patient population of this study consists of prospective, consecutive patients enrolled in the Corogene study. The details of the Corogene study and the data collection have been described in the Data Supplement and in a previous article. 14 In brief, the Corogene study included comprehensive information of 5809 patients who were assigned for coronary angiography at the Helsinki University Central Hospital between July 2006 and March 2008. The current study includes 2090 patients with ACS. The patients were followed up until death or by the end of the year 2012. The causes of death were obtained from Statistics Finland and the information of the recurrence rate of ACS from the National Hospital Discharge Registry
Genotyping and SNP Selection
Genotyping details are given in the Methods section in the Data Supplement. We selected the SNPs from the GWAS performed by CARDIOGRAMplusC4D Consortium in 2013. 3 In this study, we included the variants associated with CAD genome-wide significantly, as well as the variants (r 2 <0.2) strongly associated with CAD at a 5% false discovery rate threshold. Genetic information was available for 1768 patients; of whom, 232 had recurrent ACS, and altogether, 408 patients had a composite event of recurrent ACS or CAD death.
Calculation of GRSs
We evaluated each SNP separately in an age-and sex-adjusted Cox proportional hazards model. Bonferroni correction for multiple comparisons was used in single SNP evaluation. Thus, the corrected P-value threshold for statistical significance was 0.05/153=3.27×10 −4 . We generated 2 partially overlapping GRSs from CARDIOGRAMplusC4D results: (1) 47-SNP GRS based on known CAD loci and (2) 153-SNP GRS based on a broader set of independent variants (r 2 <0.2) strongly associated with CAD at a 5% false discovery rate threshold. 3 An additional 32-SNP GRS based on the first 32 discovered CAD loci was generated and is reported in the Data Supplement. We calculated GRSs of 32, 47, and 153 SNPs (GRS32, GRS47, and GRS153, respectively) for each individual by summing the weighted number of risk alleles of the chosen SNPs and dividing the sum by the number of SNPs. SNPs were weighted with the effect sizes reported by CARDIOGRAMplusC4D. 3 Previous research has shown that weighted GRSs can detect associations better than unweighted scores. 15 The GRSs were tested in Cox proportional hazards models first adjusted for age and sex and then for clinical variables. The clinical variables used in the adjustment were age, sex, history of hypertension, dyslipidemia, diabetes mellitus or previous MI, smoking, subtype of MI, 3-vessel disease, and congestion observed in chest x-ray. The models were tested for suspected interactions between GRSs and clinical variables. No significant interactions were found.
Statistical Methods
The numbers are presented as mean±SD or the number and percentage. Clinical variables were evaluated using univariate Cox models. Categorical variables were compared by cross-tabulation and χ 2 tests. Normally distributed scale variables were analyzed with Student t test for independent variables. Hazard ratios (HRs) and 95% confidence intervals (CIs) are reported. The Hosmer-Lemeshow goodness-of-fit test was used to evaluate the calibration of the Cox models. Calibration was good for all models (Hosmer-Lemeshow, P>0.05). The proportional hazards assumption was met. In Cox proportional hazards models, we limited the follow-up time to 5 years. We considered P values <0.05 statistically significant. We used SPSS Statistics 20.0 (SPSS, Inc, Chicago, IL) for studying baseline factors and statistical package R (version 2.15.1) for the risk models.
Results

Patient Characteristics
Of the 2090 patients with ACS, 227 (10.9%) had unstable angina pectoris, 1134 (54.3%) non-ST-segment-elevation MI (NSTEMI), and 729 (34.9%) STEMI. Patients with recurrent ACS were more likely to have either NSTEMI or unstable angina pectoris as index ACS (Table 1) . Table I in the Data Supplement shows the patient characteristics according to the composite event of recurrent ACS or CAD death. Neither locus for region 9p21 (rs1333049) nor locus for region 1q41 (rs17465637) was associated with recurrent ACS, CAD mortality, or combined end point. Also the association of the loci for ABO (rs495828) with the end points was negative.
Follow-Up
Single SNP Associations
Genetic Risk Scores
The GRSs were evaluated in age-and sex-adjusted and multivariable-adjusted Cox models (Table 2 ). GRS47 was significantly associated with recurrent ACS (P=0.009; HR, 1.199; 95% CI, 1.046-1.374). The association stayed significant after multivariable adjustment (P=0.037; HR, 1.169; 95% CI, 1.009-1.355) and after exclusion of patients with acute MI already before the index ACS (P=0.040; HR, 1.213; 95% CI, 1.009-1.459; Table III We tested the GRS associations with clinical factors and found that GRS47 was associated inversely with STEMI and smoking and GRS153 correlated positively with dyslipidemia (Table 3 ). In addition to the inverse association with STEMI and smoking, the additional GRS32 also correlated positively with 3-vessel disease ( 
Discussion
The current article reports 3 novel findings: first, a GRS constructed of previously known CAD loci (GRS47) associated with recurrent ACS independent of clinical risk factors. However, GRS47 had no association with the composite end point of recurrent ACS or CAD death when multivariable adjusted. A broader GRS (GRS153), including not only genome-wide significant SNPs but also suggestive CAD SNPs, did not correlate with either end point. Second, both GRSs were associated inversely with STEMI and GRS47 also inversely with smoking. One SNP (rs2895811) in all GRSs was associated with smoking. Third, an SNP (rs2832227) of the suggestive loci for CAD was found to be associated with recurrent ACS for the first time.
The previous evidence of GRS associations with recurrent ACS is conflicting. Tragante et al 16 found a suggestive association between a 30-CAD-SNP GRS and recurrent MI. Mega et al 17 detected an association between recurrent MI and a 27-SNP GRS in patients selected for randomized controlled trial concerning statin therapy. Labos et al 18 reported a GRS, including 30 CAD SNPs, that was not associated with recurrent events within 1 year after ACS. The SNPs included in all these 3 GRSs are either identical to ours or represent the same gene region but with a different proxy SNP with minor exceptions. Compared with the GRSs of Tragante et al 16 , Mega et al, 17 and Labos et al, 18 our GRS with 47 SNPs comprised considerably more risk variants and accordingly covered a greater proportion of the genetic predisposition to CAD. Labos et al 18 had a slightly different focus and thus a shorter follow-up than our study, which potentially explains why the association between the GRS and the recurrent ACS could not be shown. The rather limited number of recurrent events in the study by Tragante et al 16 might account for the relatively weak association found in that study. Our study, therefore, strengthens the finding that GRS comprising CAD risk SNPs can predict recurrence also in a more heterogenic population.
GRS153 had no association with either end point although it covers a larger proportion of genetic variance in CAD. This may arise from several aspects. In addition to the 47 confirmed and genome-wide significant SNPs, the GRS153 included 106 independent variants (r 2 <0.2) strongly associated with CAD at a 5% false discovery rate threshold. Thus, GRS153 included some variants likely to be false positives, which weakens its prediction capability. Because the effect of each risk variant is relatively small, even larger sample sizes are needed to detect new CAD risk variants. It is likely that the CAD risk variants first discovered hold the strongest association with CAD. Therefore, a GRS comprising only the strongest variants presumably performs better than a GRS including also weaker variants although weighted.
The GRS associations with 3-vessel disease and the inverse association with smoking and STEMI found in this In multivariable-adjusted models, the adjustment were made for age, sex, history of hypertension, dyslipidemia, diabetes mellitus or previous myocardial infarction, smoking, subtype of myocardial infarction, 3-vessel disease, and congestion observed in chest x-ray. ACS indicates acute coronary syndrome; CAD, coronary artery disease; CI, confidence interval; HR, hazard ratio; and GRS, genetic risk score. n (%) is shown for categorical variables. Mean±SD is shown for continuous variables. ACE indicates angiotensin-converting enzyme; ACS, acute coronary syndrome; AMI, acute myocardial infarction; AT, angiotensin-II; BMI, body mass index; CABG, coronary artery bypass grafting; CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; GFR, glomerular filtration rate; GP, glycoprotein; GRS, genetic risk score; LMWH, low-molecular weight heparin; MI, myocardial infarction; PCI, percutaneous coronary intervention; and TIA, transient ischemic attack.
*GFR for each patient was estimated from serum creatinine using the modification of diet in renal disease study equation. 19 Second, smokers are more prone to STEMI than NSTEMI. 20 The inverse association between STEMI and GRSs combined with these facts suggests that the background for the ACS subtypes differs. Third, CAD-related SNPs from large-scale GWAS studies are related primarily to atherosclerosis. 21 This is in concert with our findings and findings of Bjornsson et al 22 that GRSs combined of CAD risk SNPs correlate to the presence of multivessel disease.
GRSs have been shown to improve risk prediction of CAD and first MI over clinical factors in healthy or at-risk populations. [23] [24] [25] [26] [27] [28] [29] In this study, however, the addition of GRS to clinical risk model did not improve risk prediction for recurrent ACS enough to be clinically significant. This is in line with the suggestion that CAD-related SNPs from large-scale GWAS studies are related primarily to atherosclerosis and less to MI. 21 In addition to genetics, also the pathophysiology behind atherosclerosis and MI differs. Most importantly, thrombosis plays a greater role in MI pathophysiology than in CAD. Although atherosclerosis develops along multiple risk factors and age, MI is seen more often in smokers and in younger individuals with fewer risk factors. Furthermore, the incidence of the first MI at the population level is lower than the rate of recurrent MI among patients who have already had the first MI. The clinical risk scores seem to predict recurrent ACS better than the first ACS among healthy population. Therefore, GRSs may not overweigh the clinical risk prediction.
Our study suggests that the genetic risk profile might differ in smoking and nonsmoking patients with ACS. Overall, of the CAD-related SNPs we have included in the GRS, 11 are known to mediate their action through lipids and 5 by hypertension. The rest act either independently of known risk factors or their action is unknown. 30 None of these CAD-related genetic loci are known to associate with smoking. 31 In this study, only a single SNP (rs2895811) in chromosome 14 near the HHILP1 gene was associated with smoking when tested individually. In light of previous studies, our findings support the conclusion that smoking may be such an important risk factor for CAD that it can overweigh the genetic risk.
We also studied independently the 153 susceptibility loci for CAD and found locus rs2832227 in chromosome 21 to be related to recurrent ACS and the composite end point also after multivariable clinical adjustments. This locus is not an established risk locus but a suggestive locus from false discovery rate analysis. In a study by Villard et al, 32 this SNP for gene TAK1L was found associated with dilated cardiomyopathy in the discovery phase, but replication was not achieved. 32 Our finding on the association with recurrent ACS needs further studies and confirmation.
The Global Registry of Acute Coronary Events (GRACE) Genetics Study revealed several findings on the predictive value of risk variants. Risk variants at chromosome 9p21 33 and 9q34.2 (ABO gene region) 34 were found to predispose patients with ACS to adverse outcomes during a 6-month follow-up. Although a proven association with CAD in the Finnish population has been reported, 28 we found no association between recurrent ACS or the composite end point of recurrent ACS and CAD death and a risk variant either at 9p21 or at the ABO region. This finding might be explained by our limited sample size. Also the effect size of risk variants may vary across populations. In addition, we used different proxy SNPs for ABO than GRACE study. Furthermore, loci at 1p13.3 (rs599839) and 1q41 (rs17465637) have been linked to subsequent cardiovascular outcomes in patients with previous MI, 35 1p13.3 having a protective effect. We could replicate neither of these associations.
The strengths of our study include comprehensive clinical information and a complete follow-up. We did not limit our analysis to CAD variants confirmed in GWAS studies, but also evaluated a set of suggestive variants that may be informative in predicting CAD but have not exceeded the genome-wide significance level. The end points were strictly limited to CAD death and recurrent ACS only, preventing the possible bias from other cardiac causes of death.
However, there are some limitations to our study. The cohort was of Finnish origin; so, the generalizability to other populations needs confirming. We had no confirmatory population to validate the results. Also, our patient population is heterogenic, with a broad age range. It is likely that the importance of genetic predisposition is higher in a younger group of patients, and thus, the association between the recurrence and GRS would be stronger. However, dividing our patients to age groups would not have been useful because of the groups becoming too small. A part of the patients had previous acute MI. For them, the index ACS was already a recurrent ACS, which may reduce the strength of the association between the GRS and the recurrent ACS in the analysis. Thus, we adjusted the multivariable analysis concerning GRS and recurrent ACS association for previous acute MI. Table III in the Data Supplement also shows the analysis separately for patients with/without previous acute MI. A recent 1000-Genomebased meta-analysis also introduced 10 new risk variants, 36 which are not included in our GRSs. Regardless of that, of the studies about GRSs and ACS recurrence association, our GRSs still include the highest number of published CAD variants this far.
In conclusion, a GRS combined of 47 known CAD risk SNPs was associated with recurrent ACS. Smoking and STEMI were associated inversely with the GRSs. The significance of smoking in relation to genetic CAD predisposition may merit further evaluation in patients with ACS. One susceptibility locus in chromosome 21 for CAD was related to recurrent ACS and the composite end-point of recurrent ACS and CAD death. Further studies are needed to confirm this finding.
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